Algert Global LLC Janux Therapeutics, Inc. Transaction History
Algert Global LLC
- $4.25 Billion
- Q4 2024
A detailed history of Algert Global LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 64,961 shares of JANX stock, worth $2.36 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
64,961
Previous 24,472
165.45%
Holding current value
$2.36 Million
Previous $1.11 Million
212.77%
% of portfolio
0.08%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
207Shares Held
50.6MCall Options Held
158KPut Options Held
697K-
Ra Capital Management, L.P. Boston, MA10.4MShares$377 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$130 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$128 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$111 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$85.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.52B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...